secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001104659-22-116475
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma Q3 2022 loss widens to $8.6M; cash at $25.4M; SWARM-P.a. study near completion
--------------------------------------------------------------------------------

- Loss from operations $(8.6)M in Q3 2022 vs $(6.1)M in Q3 2021, driven by higher R&D spending.
- Cash and equivalents $25.4M as of Sept 30, 2022, up from $10.3M at Dec 31, 2021; expects $16.3M in MTEC grant funding.
- R&D expenses $8.4M, up from $5.6M; G&A expenses $1.6M, down from $1.8M.
- SWARM-P.a. Phase 2 MAD cohort enrollment finishing in Q4; top-line data expected early 2023.
- AP-SA02 bacteremia study enrolling Phase 1b; regulatory approvals in Australia to accelerate enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/0001104659-22-116475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/tm2226320d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer